Patients were randomly assigned via a central computerised minimisation procedure to three cycles of docetaxel ( @ mg/m ( @ ) once every @ days ) followed by three cycles of fluorouracil ( @ mg/m ( @ ) ) , epirubicin ( @ mg/m ( @ ) ) , and cyclophosphamide ( @ mg/m ( @ ) ) once every @ days ( D-FEC ) , without or with four cycles of bevacizumab ( @ mg/kg ) ( Bev + D-FEC ) .